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Abstract 
We report on a patient with breast cancer in whom there were areas of the tumor that 
were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each 
other. Depending on the area tested the results were completely different. The clinical 
implications are important. We recommend retesting a large portion of the tumor in all 
cases of initially negative test results. 
Introduction 
The importance of HER2 neu testing in breast cancer has been emphasized extensively. 
The recommended methods of testing for HER2 neu, its appropriate interpretation and 
the clinical consequences have also been the subject of extensive reviews [1, 2]. When a 
tissue sample is adequately processed and interpreted by an experienced individual, in the 
presence of adequate controls, the results of the test are deemed to be reliable and do not 
require retesting. The heterogeneity of HER2 neu expression by immunohistochemistry 
(IHC) and/or fluorescence in situ hybridization (FISH) testing has also been studied with 
discrepant results [3–5] and guidelines have been issued regarding the intratumoral 
heterogeneity of HER2 neu expression by FISH [6]. However, the simultaneous 
coexistence of areas of negative expression and a 3+ expression by IHC on immediately 
adjacent tumor cells has not been discussed. 
Case Report 
A 63-year-old woman underwent mammograms, ultrasound and magnetic resonance imaging of the 
breasts for mammographically detected, suspicious abnormalities. The larger abnormality in the left 
breast at 11 o’clock was shown to be a hyalinazing, infiltrating duct cell carcinoma of the breast with 
negative estrogen receptors (0%), negative progesterone receptors (0%) and negative HER2 neu 
oncoprotein expression (Ventana Medical Systems, Tucson, Ariz., USA), all by IHC with appropriately 
positive controls. The MIB-1 was high (76%), the CK5 was positive (70%) and the epidermal growth  
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factor receptor was also positive (90%). A biopsy of a much smaller lesion revealed lobular neoplasia. 
The patient elected to have a left mastectomy and sentinel node biopsy and a prophylactic right simple 
mastectomy. The final pathology revealed a 2.5-cm, infiltrating, poorly differentiated duct cell 
carcinoma with clear margins. The Nottingham histologic score was 8 (Grade III), the estrogen and 
progesterone receptors were again negative (0), but the HER2 neu by IHC was positive (3+). There was 
also lobular neoplasia in the vicinity. A total of 8 nodes were negative for metastasis by histology and 
IHC. The contralateral breast revealed fibrocystic mastopathy with intraductal microcalcifications and 
duct epithelial hyperplasia. The patient is Jewish Ashkenazi and has a positive family history of breast 
cancer with negative BRCA 1 and 2. The patient was started on adjuvant chemotherapy with 
trastuzumab, carboplatin and docetaxel. 
The histopathology of the tumor was reviewed again, attempting to explain the disparity of the 
results, and we found that the majority of tumor cells expressing 3+ positivity for HER2 neu by IHC 
were surrounding a defined area of the same histologic tumor that was negative for HER2 neu, by the 
same IHC. Fig. 1 shows a whole mount of the tumor on a glass slide stained with IHC for HER2 neu, 
showing malignant cells expressing 3+ positivity for HER2 neu adjacent to negative expression. 
Furthermore, in the area of HER2 neu negativity, we were able to identify the needle tract left by the 
biopsy needle (schematically represented by two parallel lines), and a small square was amplified to 
higher power showing the junction between HER2-positive and -negative zones (fig. 2). 
Discussion 
When the testing for HER2 neu results in 3+ positivity by IHC or HER2 neu gene 
amplification by FISH testing, the patient is treated with medications targeting this 
receptor. Assuming accurate testing and interpretation, these tests are rarely, if ever, 
repeated again. The heterogeneity of HER2 neu results has been partially addressed [3–6], 
but the particular variability found in this unique case has not been addressed yet. The 
clinical consequences for this individual patient would have been serious if the HER2 neu 
positivity had gone undetected. We do not know the frequency with which a disparity of 
this degree occurs, but it is not even mentioned in reviews on this subject or consensus 
guidelines published previously. We therefore assume that it must be a rare phenomenon 
or one clearly underappreciated. 
Recent tests using DNA microarray technology attempt to predict the risk of 
recurrence in patients with various cancers. The Oncotype DX (Genomic Health Inc., 
Redwood City, Calif., USA) [7] is a commonly used test, accepted by the National 
Comprehensive Center Network [8], that analyzes the expression of 21 genes in breast 
tumors and reports a score that correlates with an estimated percentage chance of distant 
tumor recurrence. Occasionally, in the practice of clinical oncology, experienced 
physicians find large inexplicable discrepancies between the risk of recurrence assessed by 
the available clinical information and their individual experience and that reported by the 
test itself. The result of the risk as assessed by the Oncotype DX relies greatly on the 
HER2 neu expression. There are also reports of patients with HER2 neu-negative breast 
cancers that have responded to therapy with trastuzumab. A central review of HER2 neu 
results has also been done in large trials with concordant results found only in 81% of the 
samples. However, the methodology did not include testing of the same specimen on 
which the original test had been done [9]. Finally, changes in HER2 neu results have also 
been reported in the same tumor at different times [10]. Cases similar to the one reported 
here offer an obvious potential explanation for these disparities and unexpected responses 
to therapy. 
The clinical consequences of failing to identify the correct expression of HER2 neu are 
serious; therefore, we suggest that in patients in whom the original biopsy results of HER2 
neu are negative, by any testing method, a retesting of a larger sample of the tumor should 
be done.  
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Fig. 1. A whole mount of the tumor on a glass slide stained with IHC for HER2 neu showing 
malignant cells expressing 3+ positivity for HER2 neu adjacent to negative expression (small square). 
Two parallel lines: schematic representation of the needle tract left by the biopsy needle. 
 
 
 
Fig. 2. Amplification of small square in figure 1. Junction between HER2-positive and -negative zones. 
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